我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
16
6 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
6
37.5%
已完成
1
6.3%
招募中
9
56.3%
暂无批准数据
- Brenus Pharma has successfully dosed the first patients in a Phase I/IIa trial evaluating STC-1010, a novel in vivo immunotherapy for unresectable, locally advanced or metastatic colorectal cancer. - The first patient completed eight weeks of treatment with no adverse events attributed to the investigational therapy, with three patients already enrolled in the study. - The international "BreAK CRC-001" trial will assess STC-1010 in combination with immunostimulatory agents and standard chemotherapy in over 80 patients, with first results expected in the first half of 2026. - The therapy targets pMMR/MSS colorectal cancer patients who have limited immunotherapy options, aiming to convert "cold" tumors into "hot" tumors responsive to immune attack.
